Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Plant proteins – e.g. – derived from legumes – algae or...
Reexamination Certificate
2002-02-01
2008-12-09
Worley, Cathy Kingdon (Department: 1638)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Plant proteins, e.g., derived from legumes, algae or...
C530S387300, C530S391700, C514S002600
Reexamination Certificate
active
07462694
ABSTRACT:
Disclosed are PAP mutants that are less toxic than wild type PAP and that exhibit depurination activity. Also disclosed are transgenic plants that procedure the PAP mutants, and methods for preparing the plants. Further disclosed are bioconjugates containing the PAP mutants, pharmaceutical compositions containing the bioconjugates, and methods of administering the compositions to treat disease.
REFERENCES:
patent: 5756322 (1998-05-01), Tumer
Honjo et al. (1997) Bull. Fac. Agr. Saga Univ., vol. 82, pp. 83-90.
Hudak et al. Generation of pokeweed an tiviral protein mutations inSaccharomyces cerevisiae: evidence that ribosome depurination is not sufficient for cytotoxicity. (2004) Nucleic Acids Research, vol. 32, pp. 4244-4256.
Zhao et al. A pokeweed antiviral protein gene in roots ofPhytolacca americana. (2005) GenBank Accession AY547315, pp. 1-2.
Lin et al. Isolation and characterization of a cDNA clone encoding the anti-viral protein fromPhytolacca americana. (1991) GenBank Accession X55383, pp. 1-2.
Uckun et al., “TXU (Anti-CD7)-Pokeweed Antiviral Protein As A Potent Inhibitor Of Human Immunodeficiency Virus”, Antimicrobial Agents and Chemotherapy, vol. 42, No. 2, pp. 383-388, Feb. 1998.
Erice et al., “Anti-Human Immunodeficiency Virus Type 1 Activity Of An Anti-CD4 Immunoconjugate Containing Pokeweed Antiviral Protein”, Antimicrobial Agents and Chemotherapy, vol. 37, No. 4, pp. 835-837, Apr. 1993.
Tumer et al., C-terminal deletion mutant of pokeweed antiviral protein inhibits viral infection but does not depurinate host ribosomes, Proc. Natl. Acad. chi. USA, vol. 94, pp. 3866-3871, Apr. 1997.
Waddick et al., “In Vitro and In Vivo Antileukemic Activity of B43-Pokeweed Antiviral Protein Against Radiation-Resistant Human B-Cell Precursor Leukemia Cells”, Blood, vol. 86, No. 11, pp. 4228-4233, Dec. 1, 1995.
Irvin et al., “Pokeweed Antiviral Protein: Ribosome Inactivation And Therapeutic Applications”, Pharmacology & Therapeutics, vol. 55, No. 3, pp. 279-302, 1992.
Uckun et al., “Toxicity, biological Activity, and Pharmacokinetics of TXU (Anti-CD7)-Pokeweed Antiviral Protein in Chimpanzees and Adult Patients Infected with Human Immunodeficiency Virus” Journal of Pharmacology & Experimental Therapeutics, vol. 291, No. 3, pp. 1301-1307, 1999.
Hudak et al., “Pokeweed Antiviral Protein Accesses Ribosomes by Binding to L3”, Journal of Biological Chemistry, vol. 274, No. 6, pp. 3859-3864, Feb. 5, 1999.
Hudak, et al. “A novel mechanism for inhibition of translation by pokeweed antiviral protein: Depurination of the capped RNA template”, RNA, vol. 6, pp. 369-380, 2000.
Schlick et al., “Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines”, FEBS Letters, vol. 472, No. 2-3, pp. 241-246, 2000.
Ago et al., Eur. J. Biochem. “X-ray structure of a pokeweed antiviral protein, coded by a new genomic clone. at 0.23 nm resolution-a mode 1 structure provides a suitable electrostatic field for substrate binding”. 225:369-374 (1994).
Cui et al., “mof4-1 is an allele of the UPF1/IFS2 gene which affects both mRNA turnover and—1 ribosomal frameshifting efficiency”. EMBO J. 15:5726-5736 (1996).
Hudak et al., “A C-terminal deletion mutant of pokeweed antiviral protein inhibits programmed +1 ribosomal frameshifting and Ty1 retrotransposition without depurinating the sarcin/ricin loop of rRNA”. Virology 279:292-301 (2001).
Hur et al., “Isolation and Characterization of Pokeweed Antiviral Protein Mutations inSaccharomyces cerevisiae: Identification of Residues Important for Toxicity”. Proc. Natl. Acad. Sci. U.S.A. 92:8448 (1995).
Lodge et al., “Broad-spectrum virus resistance in transgenic plants expressing pokeweed antiviral protein”. Proc. Natl. Acad. Sci. U.S.A. 90:7089-7093 (1993).
Hudak Katalin A.
Parikh Bijal
Tumer Nilgun E.
Kingdon Worley Cathy
Lerner David Littenberg Krumholz & Mentlik LLP
Rutgers The State University
LandOfFree
C-terminally truncated non-cytotoxic PAP mutants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-terminally truncated non-cytotoxic PAP mutants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-terminally truncated non-cytotoxic PAP mutants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4028283